论文部分内容阅读
目的 :探讨拉米夫定联合扶正化瘀胶囊治疗代偿期乙肝肝硬化临床疗效,并观察其对患者血清学指标和肝功能及免疫功能的影响。方法 :回顾性分析2014年8月~2016年8月52例诊断为代偿期乙肝肝硬化患者诊治情况,其中采用维生素类药物、甘草酸二铵肠溶胶囊及拉米夫定片口服治疗者为对照组(26例);于对照组治疗基础上采用扶正化瘀胶囊治疗者为治疗组(26例)。采用实验室检查治疗前、后肝功能变化,检测两组患者治疗前、后免疫功能;并统计两组临床疗效及安全性。结果 :两组肝功能各项指标较治疗前明显下降,治疗组各项指标下降程度均优于对照组,P<0.05。两组患者治疗后免疫功能指标较治疗前明显改善,治疗组各项指标改善程度均优于对照组,P<0.05。治疗组临床治疗总有效率93.31%,明显高于对照组57.69%,χ2=8.60,P=0.01;治疗期间均无严重性不良反应发生。结论:采用拉米夫定片联合扶正化瘀胶囊治疗代偿期乙肝肝硬化具有明显疗效,且较安全,有利于提高患者免疫功能。
Objective: To investigate the clinical efficacy of lamivudine combined with Fuzhenghuayu Capsule in the treatment of decompensated hepatitis B cirrhosis, and to observe its effects on serum markers, liver function and immune function. Methods: The diagnosis and treatment of patients with decompensated hepatitis B cirrhosis from August 2014 to August 2016 were retrospectively analyzed. Among them, vitamin drugs, diammonium glycyrrhizinate enteric-coated capsules and oral treatment of lamivudine tablets For the control group (26 cases); on the basis of the control group, Fuzhenghuayu capsule was used as the treatment group (26 cases). The changes of liver function before and after treatment were detected by laboratory tests. The immune function of the two groups before and after treatment was detected. The clinical efficacy and safety of the two groups were also calculated. Results: The indexes of liver function in both groups were significantly lower than those before treatment, and the indexes in the treatment group decreased more significantly than those in the control group (P <0.05). After treatment, the immune function indexes in both groups were significantly improved compared with that before treatment, and the improvement of various indexes in the treatment group was better than that in the control group (P <0.05). The total effective rate of clinical treatment in the treatment group was 93.31%, which was significantly higher than that in the control group (57.69%, χ2 = 8.60, P = 0.01). No adverse reactions occurred during the treatment. Conclusion: Lamivudine combined with Fuzhenghuayu capsule in the treatment of decompensated hepatitis B cirrhosis has obvious curative effect, which is safer and helps to improve the immune function of patients.